129 related articles for article (PubMed ID: 18247404)
1. The UGT2B17 gene deletion is not associated with prostate cancer risk.
Olsson M; Lindström S; Häggkvist B; Adami HO; Bälter K; Stattin P; Ask B; Rane A; Ekström L; Grönberg H
Prostate; 2008 Apr; 68(5):571-5. PubMed ID: 18247404
[TBL] [Abstract][Full Text] [Related]
2. Deletion polymorphism of the UGT2B17 gene is associated with increased risk for prostate cancer and correlated to gene expression in the prostate.
Karypidis AH; Olsson M; Andersson SO; Rane A; Ekström L
Pharmacogenomics J; 2008 Apr; 8(2):147-51. PubMed ID: 17387331
[TBL] [Abstract][Full Text] [Related]
3. Deletion polymorphism of UDP-glucuronosyltransferase 2B17 and risk of prostate cancer in African American and Caucasian men.
Park J; Chen L; Ratnashinge L; Sellers TA; Tanner JP; Lee JH; Dossett N; Lang N; Kadlubar FF; Ambrosone CB; Zachariah B; Heysek RV; Patterson S; Pow-Sang J
Cancer Epidemiol Biomarkers Prev; 2006 Aug; 15(8):1473-8. PubMed ID: 16896035
[TBL] [Abstract][Full Text] [Related]
4. Prostate cancer with variants in CYP17 and UGT2B17 genes: a meta-analysis.
Cai L; Huang W; Chou KC
Protein Pept Lett; 2012 Jan; 19(1):62-9. PubMed ID: 21919858
[TBL] [Abstract][Full Text] [Related]
5. The UGT2B17 gene deletion polymorphism and risk of prostate cancer. A case-control study in Caucasians.
Gallagher CJ; Kadlubar FF; Muscat JE; Ambrosone CB; Lang NP; Lazarus P
Cancer Detect Prev; 2007; 31(4):310-5. PubMed ID: 17935910
[TBL] [Abstract][Full Text] [Related]
6. Association of Genetic Polymorphisms in UDP-Glucuronosyltransferases 2B17 with the Risk of Pancreatic Cancer in Chinese Han Population.
Che X; Yu D; Wu Z; Zhang J; Chen Y; Han Y; Wang C; Qi J
Clin Lab; 2015; 61(12):1905-10. PubMed ID: 26882814
[TBL] [Abstract][Full Text] [Related]
7. Association between polymorphisms in HSD3B1 and UGT2B17 and prostate cancer risk.
Park JY; Tanner JP; Sellers TA; Huang Y; Stevens CK; Dossett N; Shankar RA; Zachariah B; Heysek R; Pow-Sang J
Urology; 2007 Aug; 70(2):374-9. PubMed ID: 17826523
[TBL] [Abstract][Full Text] [Related]
8. A novel polymorphism in a forkhead box A1 (FOXA1) binding site of the human UDP glucuronosyltransferase 2B17 gene modulates promoter activity and is associated with altered levels of circulating androstane-3α,17β-diol glucuronide.
Hu DG; Gardner-Stephen D; Severi G; Gregory PA; Treloar J; Giles GG; English DR; Hopper JL; Tilley WD; Mackenzie PI
Mol Pharmacol; 2010 Oct; 78(4):714-22. PubMed ID: 20628005
[TBL] [Abstract][Full Text] [Related]
9. Genetic variations in UGT2B28, UGT2B17, UGT2B15 genes and the risk of prostate cancer: A case-control study.
Habibi M; Mirfakhraie R; Khani M; Rakhshan A; Azargashb E; Pouresmaeili F
Gene; 2017 Nov; 634():47-52. PubMed ID: 28882566
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of UDP-glucuronosyltransferase 2B17 (UGT2B17) and dihydrofolate reductase (DHFR) genes deletion and the expression level of NGX6 mRNA in breast cancer.
Eskandari-Nasab E; Hashemi M; Rezaei H; Fazaeli A; Mashhadi MA; Moghaddam SS; Arbabi F; Jahantigh M; Taheri M
Mol Biol Rep; 2012 Dec; 39(12):10531-9. PubMed ID: 23053953
[TBL] [Abstract][Full Text] [Related]
11. UDP-glucuronosyltransferase 2B17 genotyping in Japanese athletes and evaluation of the current sports drug testing for detecting testosterone misuse.
Okano M; Ueda T; Nishitani Y; Kano H; Ikekita A; Kageyama S
Drug Test Anal; 2013 Mar; 5(3):166-81. PubMed ID: 22887913
[TBL] [Abstract][Full Text] [Related]
12. A common deletion in the uridine diphosphate glucuronyltransferase (UGT) 2B17 gene is a strong determinant of androgen excretion in healthy pubertal boys.
Juul A; Sørensen K; Aksglaede L; Garn I; Rajpert-De Meyts E; Hullstein I; Hemmersbach P; Ottesen AM
J Clin Endocrinol Metab; 2009 Mar; 94(3):1005-11. PubMed ID: 19088161
[TBL] [Abstract][Full Text] [Related]
13. The UDP-glucuronosyltransferase 2B17 gene deletion polymorphism: sex-specific association with urinary 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol glucuronidation phenotype and risk for lung cancer.
Gallagher CJ; Muscat JE; Hicks AN; Zheng Y; Dyer AM; Chase GA; Richie J; Lazarus P
Cancer Epidemiol Biomarkers Prev; 2007 Apr; 16(4):823-8. PubMed ID: 17416778
[TBL] [Abstract][Full Text] [Related]
14. The effect of copy number variation in the phase II detoxification genes UGT2B17 and UGT2B28 on colorectal cancer risk.
Angstadt AY; Berg A; Zhu J; Miller P; Hartman TJ; Lesko SM; Muscat JE; Lazarus P; Gallagher CJ
Cancer; 2013 Jul; 119(13):2477-85. PubMed ID: 23575887
[TBL] [Abstract][Full Text] [Related]
15. The uridine diphosphate glucuronosyltransferase 2B15 D85Y and 2B17 deletion polymorphisms predict the glucuronidation pattern of androgens and fat mass in men.
Swanson C; Mellström D; Lorentzon M; Vandenput L; Jakobsson J; Rane A; Karlsson M; Ljunggren O; Smith U; Eriksson AL; Bélanger A; Labrie F; Ohlsson C
J Clin Endocrinol Metab; 2007 Dec; 92(12):4878-82. PubMed ID: 17698910
[TBL] [Abstract][Full Text] [Related]
16. Effect of UGT2B17 deletion polymorphism on prognosis in pediatric cancer.
Ishimaru S; Yuza Y; Kaneko T; Urashima M
Pediatr Int; 2017 Apr; 59(4):427-431. PubMed ID: 27805301
[TBL] [Abstract][Full Text] [Related]
17. Substantial advantage of a combined Bayesian and genotyping approach in testosterone doping tests.
Schulze JJ; Lundmark J; Garle M; Ekström L; Sottas PE; Rane A
Steroids; 2009 Mar; 74(3):365-8. PubMed ID: 19056415
[TBL] [Abstract][Full Text] [Related]
18. Bioavailability of testosterone enanthate dependent on genetic variation in the phosphodiesterase 7B but not on the uridine 5'-diphospho-glucuronosyltransferase (UGT2B17) gene.
Ekström L; Schulze JJ; Guillemette C; Belanger A; Rane A
Pharmacogenet Genomics; 2011 Jun; 21(6):325-32. PubMed ID: 21383644
[TBL] [Abstract][Full Text] [Related]
19. Differential expression of the androgen-conjugating UGT2B15 and UGT2B17 enzymes in prostate tumor cells during cancer progression.
Pâquet S; Fazli L; Grosse L; Verreault M; Têtu B; Rennie PS; Bélanger A; Barbier O
J Clin Endocrinol Metab; 2012 Mar; 97(3):E428-32. PubMed ID: 22170718
[TBL] [Abstract][Full Text] [Related]
20. Potentially harmful advantage to athletes: a putative connection between UGT2B17 gene deletion polymorphism and renal disorders with prolonged use of anabolic androgenic steroids.
Deshmukh N; Petróczi A; Barker J; Székely AD; Hussain I; Naughton DP
Subst Abuse Treat Prev Policy; 2010 Apr; 5():7. PubMed ID: 20429943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
